DURECT's CMO Dr Joseph Stauffer resigns
This article was originally published in Scrip
Dr Joseph Stauffer, DURECT Corporation's chief medical officer and executive vice-president of corporate strategy, has resigned effective 21 June 2011. Dr Stauffer will continue as a consultant to DURECT, a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, at least until 31 December 2011.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.